miRagen Announces New Clinical Data for Cobomarsen in ATLL Patients at the 19th Annual HTLV Congress in Lima, Peru
Published on: Thursday 25 April 2019
biomarkers that have been associated with poor prognosis were reduced following cobomarsen treatment Cobomarsen continues to show good tolerability with no serious adverse events deemed related to ...